Integrated BioPharma, Inc. reported a net sales increase of 8% for the fiscal year ending June 30, 2025, reaching approximately $54.4 million, up from $50.3 million in the previous year. This growth was driven primarily by the Contract Manufacturing Segment, which saw a revenue increase of $3.1 million, attributed to higher sales to major customers, including Life Extension Quality Supplements and Herbalife Nutrition. The company’s profitability also improved, with operating income rising to approximately $2 million from $251,000 in the prior year, resulting in a net income of $808,000 compared to $112,000 in 2024.
The company experienced a notable shift in its customer concentration, with approximately 84% of consolidated net sales derived from two major customers in 2025, compared to 90% in 2024. Life Extension and Herbalife accounted for 62% and 26% of the Contract Manufacturing Segment's net sales, respectively. The company also reported a decrease in selling and administrative expenses by 2.5%, reflecting cost management efforts, which contributed to the improved operating income.
Operationally, Integrated BioPharma maintained a workforce of approximately 153 employees as of September 2025, with a significant portion covered by a collective bargaining agreement set to expire in August 2026. The company has also entered into a development and supply agreement with Herbalife, effective until December 2025, which allows for the development and supply of nutritional products, although it does not guarantee specific order quantities. The company’s cash position improved significantly, with cash at the end of the fiscal year totaling $3.6 million, up from $1.7 million in 2024.
Looking ahead, Integrated BioPharma anticipates continued growth driven by its core business segments and strategic customer relationships. However, the company acknowledges potential challenges, including inflationary pressures and supply chain disruptions that could impact margins and operational efficiency. The management remains focused on maintaining a competitive pricing structure while navigating the evolving market conditions and regulatory landscape affecting the nutraceutical industry.
About INTEGRATED BIOPHARMA INC
Integrated BioPharma, Inc. manufactures, distributes, and markets vitamins, nutritional supplements, and herbal products primarily for customers in the U.S. and Luxembourg. Its core segments include contract manufacturing and related services, serving health and wellness markets. The company emphasizes product quality, regulatory compliance, and niche market focus, operating with a small, experienced team and leveraging strategic supplier relationships in a highly competitive industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.